Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3530-3539

  Rojo, Federico ^a,b   González Navarrete, Irene ^a   Bragado, Rafael ^b   Dalmases, Alba ^a   Menéndez, Silvia ^a   Cortes Sempere, Maria ^c   Suárez, Cristina ^a   Oliva, Cristina ^a   Servitja, Sonia ^a   Rodriguez Fanjul, Vanesa ^c   Sánchez Pérez, Isabel ^c   Campas, Clara ^a   Corominas, Josep Maria ^a,d   Tusquets, Ignasi ^a   Bellosillo, Beatriz ^a,d   Serrano, Sergi ^a,d   Perona, Rosario ^c   Rovira, Ana ^a   Albanell, Joan ^a  

^a HOSPITAL DEL MAR   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ARTICLE; BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER CELL; CANCER CELL CULTURE; CANCER RELAPSE; CARCINOMA IN SITU; CELL ASSAY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME REPRESSION; EX VIVO STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DOXORUBICIN; DUAL SPECIFICITY PHOSPHATASE 1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KAPLAN-MEIERS ESTIMATE; NEOPLASM RECURRENCE, LOCAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 66149167313     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2070     Document Type: Article

References (51)

1. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006;56:168-183 (Pubitemid 43847927)
2. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784-796
3. Wu GS. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 2007;26:579-585 (Pubitemid 350115109)
4. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008;27:253-261
5. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases - regulating the immune response. Nat Rev Immunol 2007;7:202-212 (Pubitemid 46310479)
6. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-3290 (Pubitemid 46763021)
7. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-185
8. Slack DN, Seternes OM, Gabrielsen M, Keyse SM. Distinct binding determinants for ERK2/p38α and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1. J Biol Chem 2001;276:16491-16500 (Pubitemid 37391699)
9. Hutter D, Chen P, Barnes J, Liu Y. Catalytic activation of mitogen-activated protein (MAP) kinase phosphatase-1 by binding to p38 MAP kinase: critical role of the p38 C-terminal domain in its negative regulation. Biochem J 2000;352 Pt 1:155-163
10. Brondello JM, Pouyssegur J, McKenzie FR. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 1999;286:2514-2517 (Pubitemid 30026341)
11. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007;26:3203-3213 (Pubitemid 46763015)
12. Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 2002;297:1018-1023
13. Liao Q, Guo J, Kleeff J, et al. Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology 2003;124:1830-1845 (Pubitemid 36666779)
14. Chattopadhyay S, Machado-Pinilla R, Manguan-Garcia C, et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 2006;25:3335-3345 (Pubitemid 43846318)
15. Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007;67:4459-4466 (Pubitemid 46815096)
16. Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 2004;66:1478-1490 (Pubitemid 39564774)
17. Mizuno R, Oya M, Shiomi T, Marumo K, Okada Y, Murai M. Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells. J Urol 2004;172:723-727 (Pubitemid 38900249)
18. Wu W, Pew T, Zou M, Pang D, Conzen SD. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 2005;280:4117-4124 (Pubitemid 40288576)
19. Vogt A, McDonald PR, Tamewitz A, et al. A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther 2008;7:330-340
20. Codony-Servat J, Tapia MA, Bosch M, et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006;5:665-675
21. Awada A, Albanell J, Canney PA, et al. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 2008;98:1500-1507
22. Chen YW, Huang SC, Lin-Shiau SY, Lin JK. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 2005;26:1296-1306 (Pubitemid 41417909)
23. Shi YY, Small GW, Orlowski RZ. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 2006;100:33-47.
24. Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ. Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 2003;307:861-869 (Pubitemid 37494202)
25. Gonzalez-Santiago L, Suarez Y, Zarich N, et al. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ 2006;13:1968-1981
26. Loda M, Capodieci P, Mishra R, et al. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 1996;149:1553-1564 (Pubitemid 26363962)
27. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003;191:229-237
28. Vogt A, Tamewitz A, Skoko J, Sikorski RP, Giuliano KA, Lazo JS. The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cellactive inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem 2005;280:19078-19086 (Pubitemid 41379614)
29. Tierno MB, Johnston PA, Foster C, et al. Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nat Protoc 2007;2:1134-1144 (Pubitemid 46901292)
30. Di Nicolantonio F, Knight LA, Whitehouse PA, et al. The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. Mol Cancer Ther 2004;3:1631-1637 (Pubitemid 40136719)
31. van der Kuip H, Murdter TE, Sonnenberg M, et al. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 2006;6:86.
32. Beltman J, McCormick F, Cook SJ. The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase. J Biol Chem 1996;271:27018-27024 (Pubitemid 26359119)
33. Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61:6500-6510 (Pubitemid 32783257)
34. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-3636
35. Dalton LW, Pinder SE, Elston CE, et al. Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol 2000;13:730-735 (Pubitemid 30470161)
36. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145 (Pubitemid 350003059)
37. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847 (Pubitemid 28331029)
38. Piazza E, Donelli MG, Broggini M, et al. Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy. Cancer Treat Rep 1980;64:845-854 (Pubitemid 11139821)
39. Wu JJ, Bennett AM. Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. J Biol Chem 2005;280:16461-16466 (Pubitemid 40616777)
40. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinibin tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24:4309-4316 (Pubitemid 46630789)
41. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002;161:1557-1565 (Pubitemid 35265516)
42. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18:207-208 (Pubitemid 34145055)
43. Wang J, Zhou JY, Wu GS. ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 2007;67:11933-11941
44. Wang Z, Xu J, Zhou JY, Liu Y, Wu GS. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res 2006;66:8870-8877 (Pubitemid 44449205)
45. Stanciu M, DeFranco DB. Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line. J Biol Chem 2002;277:4010-4017
46. Sanchez-Perez I, Martinez-Gomariz M, Williams D, Keyse SM, Perona R. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 2000;19:5142-5152
47. Wang Z, Cao N, Nantajit D, Fan M, Liu Y, Li JJ. MKP-1 represses JNK-mediated apoptosis via NF-κB regulation. J Biol Chem 2008.
48. Cui Y, Parra I, Zhang M, et al. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 2006;66:5950-5959 (Pubitemid 43927151)
49. Latta EK, Tjan S, Parkes RK, O'Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002;15:1318-1325 (Pubitemid 35463000)
50. Denkert C, Schmitt WD, Berger S, et al. Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer 2002;102:507-513 (Pubitemid 35316006)
51. Vicent S, Garayoa M, Lopez-Picazo JM, et al. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 2004;10:3639-3649 (Pubitemid 38697597)